Waystar Holding Corp. Common Stock
WAY
$29.18
+2.93%
Waystar Holding Corp. provides mission-critical cloud software that automates the healthcare payments workflow — from pre-service patient engagement and eligibility checks through claims processing, denial management, and post-service remittance and reconciliation — for providers, payers, and patients across the United States, Puerto Rico, and other U.S. territories. The company occupies a sticky, high-switching-cost position as an enterprise-grade revenue-cycle-management platform, competing in the healthcare information services industry where scale, payer connectivity, and data integrity create meaningful network moats. The current investor narrative centers on Waystar's transition from a levered, newly public roll-up into a profitable, cash-generative compounder: revenue growth re-accelerated to roughly 21% year-over-year in the most recent quarter, gross margins are climbing toward 70%, and management has been paying down debt and buying back stock. Debate now hinges on whether that acceleration is durable — driven by cross-sell of newer AI-enabled automation and payment modules — or flattered by pricing and acquisition contribution, with the stock's weak one-year performance reflecting earlier de-rating even as the business fundamentals have visibly improved.…
WAY
Waystar Holding Corp. Common Stock
$29.18
Investment Opinion: Should I buy WAY Today?
Rating: Buy. Waystar is a mission-critical, subscription-heavy healthcare payments platform growing revenue 21.21% YoY with 69.53% gross margins and $264.1 million of trailing free cash flow, yet it trades at roughly 10.4x the $2.735 consensus FY EPS and 18.61x EV/EBITDA — near the bottom of its post-IPO valuation band even as the stock sits at 52-week highs. The six-analyst consensus is uniformly Buy-equivalent (Freedom Capital, Truist, Evercore ISI, TD Cowen, Canaccord, KeyBanc, RBC), with only Barclays at Equal Weight, and the tight ~8% EPS estimate spread ($2.672-$2.881) signals conviction rather than uncertainty.
Supporting evidence is broad: revenue accelerated from $268.7 million in Q3 2025 to $325.6 million in Q3 2026 with steady sequential gains ($313.9M → $319.7M → $325.6M), gross margin expanded from 68.31% to 69.53% YoY, Q3 free cash flow of $93.9 million converted at 90.4% of operating cash flow, and debt-to-equity is a modest 0.384 with $20.7 million of buybacks and $3.5 million of debt repaid in the quarter. The valuation re-rating is stark versus its own history — PS has fallen from 25.94x in Q4 2024 to 5.30x today and PE from 81.88x in Q4 2025 to 39.59x in Q3 2026 — meaning earnings and cash flow have grown faster than the share price. At $28.35 the stock trades at roughly 10.4x consensus EPS, leaving substantial room for multiple expansion if the forward earnings step-up is delivered.
Three risks could invalidate the thesis: the forward EPS of $2.735 must materialize against trailing GAAP EPS of just $0.019, interest expense of ~$19-$21 million per quarter consumes a large share of pre-tax income (interest coverage ~3.2x), and the stock has already roughly doubled off its $17.31 June low, leaving little margin at $29.69 resistance with a -56.31% historical max drawdown. The rating would upgrade to a stronger Buy if Q4 confirms margin expansion and cross-sell momentum with interest costs falling, and would downgrade to Hold if revenue growth decelerates below 15% or forward EPS estimates slip toward the $2.672 low end. On balance, the stock is fairly valued to modestly undervalued relative to its own history and cheap on forward earnings — a favorable risk/reward for investors who can tolerate the volatility.
Sign up to view all
WAY 12-Month Price Forecast
The forward setup favors the bulls: revenue is accelerating rather than decelerating, gross margins are climbing toward 70%, and the stock trades near the bottom of its post-IPO valuation band at roughly 10.4x consensus EPS despite sitting at 52-week highs. The principal uncertainty is the gap between trailing GAAP EPS of $0.019 and forward EPS of $2.735, which requires interest costs to fall and operating leverage to materialize — a plausible but not guaranteed step-change given ~$19-$21 million of quarterly interest expense. Analyst sentiment is uniformly constructive with tight estimate dispersion, though thin six-analyst coverage and the lone Barclays downgrade mean conviction is comfortable rather than rising. I would upgrade to high confidence if Q4 confirms gross margin above 70% and forward EPS guidance at or above $2.80, and would downgrade to neutral if revenue growth slips below 15% or the stock breaks below the $24-$25 support shelf.
Wall Street consensus
Coverage is moderate but uniformly constructive: six analysts contribute estimates, and the institutional ratings log shows a wall of Buy-equivalent calls — Freedom Capital Markets (Buy), Truist (Buy), Evercore ISI (Outperform), TD Cowen (Buy), Canaccord (Buy), KeyBanc (Overweight), and RBC (Outperform) — with the only neutral voice being Barclays, which downgraded to Equal Weight from Overweight on September 15, 2026. The consensus leans clearly bullish, and the estimate dispersion is tight: FY EPS estimates range from $2.672 to $2.881 around an average of $2.735 (a spread of just ~8%), while revenue estimates range from $1.845 billion to $1.956 billion around $1.878 billion (a ~6% spread). A specific average price target is not provided in the data, so implied upside to a consensus target cannot be calculated; however, at $28.35 the stock trades at roughly 10.4x the $2.735 consensus EPS, which on its face leaves substantial room for multiple expansion if the earnings are delivered. The tightness of the estimate range signals strong conviction rather than uncertainty — analysts broadly agree on the trajectory — and the cluster of reiterations in early November (post-Q3 earnings) indicates the quarter reinforced rather than challenged the bull case. The high end of the EPS range ($2.881) would imply roughly 9.8x earnings at the current price, assuming modest multiple expansion and continued margin delivery, while the low end ($2.672) implies about 10.6x and likely bakes in slower cross-sell, higher interest expense, or margin compression from R&D and S&M investment. The principal risk signal is the Barclays downgrade and the absence of any recent upgrades, suggesting the sell-side is comfortable but not adding to conviction; with only six analysts and no published target range, price discovery may be less efficient than for larger-cap peers, and the stock's high volatility (a -56.31% max drawdown) means target revisions could move shares sharply in either direction.
Bulls vs Bears: WAY Investment Factors
The bull case currently has stronger evidence: revenue is accelerating at 21.21% YoY, gross margins are expanding to 69.53%, free cash flow is robust at $264.1 million TTM with 90.4% conversion, and the stock trades at just ~10.4x consensus forward EPS and 18.61x EV/EBITDA — multiples near the bottom of its post-IPO band even as the price sits at 52-week highs. The bear case rests largely on optics (a 51.98x trailing PE on depressed GAAP EPS), a persistent ~$19-21 million quarterly interest burden, and a stock that has already doubled off its June low, leaving it vulnerable to consolidation at $29.69 resistance. The single most important tension is whether the forward EPS of $2.735 is achievable — if the earnings step-up is delivered, the stock is cheap; if cross-sell and margin delivery disappoint, the trailing multiple is a warning rather than an artifact. Analyst sentiment is uniformly constructive (six Buy-equivalent calls, tight ~8% EPS estimate spread), which tilts the weight of evidence to the bull side, but the thin coverage and Barclays downgrade mean conviction is comfortable rather than rising.
Bullish
- Revenue re-accelerating to 21% YoY: Q3 2026 revenue of $325.6 million grew 21.21% year-over-year versus $268.7 million in Q3 2025, and the sequential cadence ($313.9M → $319.7M → $325.6M across Q1-Q3) shows steady quarter-over-quarter expansion on top of that elevated rate. This is acceleration, not deceleration, which is rare for a company at Waystar's scale.
- Multiples at historic lows despite price highs: PS has collapsed from 25.94x in Q4 2024 and 14.94x in Q3 2026 to 5.30x on the current market-cap basis, while PE fell from 81.88x in Q4 2025 to 39.59x in Q3 2026 and PB from 2.05x to 1.20x. The stock trades at the top of its 52-week range ($28.35 vs. $29.69 high) yet near the bottom of its post-IPO valuation band — earnings and cash flow have grown faster than the share price.
- Strong cash generation and deleveraging: Trailing free cash flow is $264.1 million, with Q3 alone generating $93.9 million of FCF on $103.9 million of operating cash flow (a 90.4% conversion rate). The company repurchased $20.7 million of stock and repaid $3.5 million of debt in Q3 while growing cash to $55.0 million, and debt-to-equity is a modest 0.384.
- Gross margins climbing toward 70%: Q3 2026 gross margin reached 69.53%, up from 68.31% in Q3 2025 and 67.41% in Q4 2024, on gross profit of $226.4 million. Expanding gross margins on 21% revenue growth demonstrates real operating leverage in a recurring, subscription-heavy model ($180.7 million of Q3 revenue was subscription and circulation).
Bearish
- Trailing PE of 52x looks expensive: The trailing PE of 51.98x is rich on GAAP earnings, and trailing EPS of just $0.019 makes the trailing multiple a poor guide. The entire bull case rests on the forward EPS of $2.735 materializing — a dramatic jump that requires interest costs to fall, operating leverage to kick in, and one-time items to roll off.
- Interest expense still a heavy drag: Interest expense ran roughly $19-$21 million per quarter in 2026 ($19.3M in Q3, $19.6M in Q2, $20.6M in Q1), consuming a large share of the $41.97 million Q3 pre-tax income. Interest coverage of roughly 3.2x is adequate but not generous, making continued EBITDA growth and deleveraging the key levers for equity value.
- Net margin oscillating downward: Quarterly net margin fell from 13.79% in Q1 to 12.78% in Q2 to 9.53% in Q3 2026, pressured by a $20.3 million R&D step-up and $52.0 million in sales and marketing. ROE of just 2.89% reflects a goodwill-and-intangible-heavy balance sheet from the company's leveraged history.
- High volatility and deep drawdown history: The stock has a maximum drawdown of -56.31% and remains down 20.81% over one year despite roughly doubling off its $17.31 June 2026 low. At $28.35 it sits at essentially 100% of its 52-week range, leaving little margin for error at resistance of $29.69.
WAY Technical Analysis
Waystar is in a powerful recovery uptrend following a deep drawdown, with the stock at $28.35 sitting roughly 100% of its 52-week range — essentially at the highs — after a 1-year change of -20.81% that masks a violent V-shaped rebound from a maximum drawdown of -56.31%. The 180-day price series shows a bottom near $17.31 in late June 2026 followed by a near-relentless climb to the current $28.35, meaning the stock has roughly doubled off its low while still being down over 20% year-over-year; that positioning signals momentum leadership rather than a falling knife, but also leaves little margin for error at the top of the range. The 52-week high of $29.69 (set November 4) is the immediate reference point, and a clean breakout above it would confirm the recovery as a new leg higher rather than a mean-reversion bounce. Short-term momentum is decisively positive and accelerating: +10.01% over the past month, +17.00% over three months, and +32.60% over six months, with the 1-month gain outpacing the 3-month gain, which itself outpaces the 6-month figure — a classic acceleration signature. Critically, this diverges sharply from the -20.81% one-year return, a bullish divergence that typically signals trend reversal rather than a temporary pullback, and relative strength confirms it: WAY has outperformed SPY by +15.00 percentage points over one month, +21.91 points over three months, and +33.14 points over six months, even as its 1-year relative strength remains -30.40 points. The lone caution is the most recent session, a -1.84% pullback from $28.88 to $28.35 on volume of roughly 1.27 million shares, which looks like normal consolidation at resistance rather than distribution. Key levels are well defined: support sits at the $17.31 June low, with intermediate support around the $24-$25 shelf that contained the September pullback, while resistance is the $29.69 November high; a breakout above $29.69 would target blue-sky territory and validate the fundamental re-rating, whereas a breakdown below $24 would break the sequence of higher lows and suggest the rally is exhausted. Beta is not available in the provided data, but the -56.31% maximum drawdown and the roughly 70% move off the low within five months make clear this is a high-volatility, high-beta name that demands smaller position sizing and wider stops than a market-average equity.
Beta
—
—
Max Drawdown
-56.3%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-19.4%
Cumulative gain past year
| Period | WAY Return | S&P 500 |
|---|---|---|
| 1m | +9.4% | -3.3% |
| 3m | +20.1% | -2.3% |
| 6m | +56.1% | +1.4% |
| 1y | -19.4% | +12.2% |
| ytd | -7.0% | +10.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAY Fundamental Analysis
Revenue is growing briskly and, importantly, accelerating: Q3 2026 revenue of $325.6 million rose 21.21% year-over-year versus $268.7 million in Q3 2025, and the sequential cadence — $313.9 million in Q1, $319.7 million in Q2, $325.6 million in Q3 — shows steady quarter-over-quarter expansion on top of that elevated growth rate. The subscription and circulation segment contributed $180.7 million, underscoring that the bulk of the business is recurring, contracted revenue rather than transactional volume, which underpins visibility. Full-year consensus revenue of approximately $1.878 billion (range $1.845-$1.956 billion) implies continued double-digit growth, and the combination of a sticky installed base, cross-sell into payments and AI-driven automation, and pricing power supports the view that growth is structural rather than cyclical. Profitability is solid and improving: Q3 2026 net income was $31.0 million (a 9.53% net margin) on gross profit of $226.4 million, a 69.53% gross margin that has expanded from 68.31% in Q3 2025 and 67.41% in Q4 2024. Operating income of $61.3 million (18.81% operating margin) was pressured sequentially by a $20.3 million R&D step-up and $52.0 million in sales and marketing, but the trailing operating margin of 22.68% and gross margin of 68.33% are strong for healthcare information services, where high-60s gross margins and low-20s operating margins are typical of scaled software platforms. The quarterly net margin has oscillated — 13.79% in Q1, 12.78% in Q2, 9.53% in Q3 — largely on interest expense of roughly $19-$21 million per quarter and tax timing, but the direction of gross margin and EBITDA dollars ($102.7 million in Q3) is clearly upward. The balance sheet and cash engine are healthy: debt-to-equity is just 0.384, the current ratio is 1.41, and trailing free cash flow is $264.1 million, with Q3 alone generating $93.9 million of FCF on $103.9 million of operating cash flow (a 90.4% FCF conversion rate). The company is self-funding — it repurchased $20.7 million of stock in Q3 and repaid $3.5 million of debt while still growing cash to $55.0 million — though ROE of 2.89% remains low, reflecting a large goodwill-and-intangible-heavy balance sheet from its leveraged history. Interest coverage of roughly 3.2x is adequate but not generous, making continued EBITDA growth and deleveraging the key levers for equity value.
Quarterly Revenue
$325624000.0B
2026-09
Revenue YoY Growth
+21.2%
YoY Comparison
Gross Margin
69.5%
Latest Quarter
Free Cash Flow
$264050000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAY Overvalued?
Because Waystar is profitable (Q3 2026 net income of $31.0 million; trailing EPS of $0.019), the PE ratio is the appropriate primary metric, and it tells a nuanced story: the trailing PE of 51.98x is rich, but the forward PE of -0.089 in the provided data is clearly a data artifact (a negative PEG-derived value), so the more reliable forward signal is consensus EPS of $2.735 against the $28.35 price, implying a forward multiple of roughly 10.4x — a dramatic compression from trailing levels. That enormous trailing-to-forward gap implies the market expects earnings to multiply as interest costs fall, operating leverage kicks in, and one-time items roll off; if delivered, the stock is inexpensive on forward earnings, but the gap also signals that trailing GAAP earnings are a poor guide to the underlying economics. On the other metrics, the stock trades at 5.30x sales, 1.50x book, 18.82x price-to-cash-flow, and 18.61x EV/EBITDA — the EV/EBITDA multiple being the cleanest read on a levered, D&A-heavy software business and one that is reasonable for a high-teens-growth healthcare IT platform. Peer comparison is constrained because the provided valuation dataset contains no explicit industry-average multiples; however, against the stock's own history the re-rating is stark. The historical ratios show PS collapsing from 25.94x in Q4 2024 and 24.61x in Q3 2025 to 14.94x in Q3 2026 (and 5.30x on the current market-cap basis), while PE fell from 81.88x in Q4 2025 to 39.59x in Q3 2026 and PB from 2.05x to 1.20x — meaning the stock now sits near the bottom of its own post-IPO valuation band despite trading at the top of its price range. That combination — price at 52-week highs but multiples at historical lows — indicates earnings and cash flow have grown faster than the share price, a classic setup where either the market is correctly discounting decelerating growth or a value opportunity is emerging; the 18.61x EV/EBITDA and ~10x forward EPS suggest the latter is at least plausible, provided the forward earnings estimate of $2.735 proves achievable.
PE
52.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~83x
vs. Industry Avg
25.9x
Industry PE ~25.9x*
EV/EBITDA
18.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the gap between trailing and forward earnings. Trailing GAAP EPS of $0.019 produces a 51.98x PE, and the bull case depends entirely on forward EPS of $2.735 materializing — a step-change that requires interest costs to fall and one-time items to roll off. Interest expense of roughly $19-$21 million per quarter ($19.3M in Q3 2026) consumes a large share of pre-tax income, and interest coverage of ~3.2x is adequate but not generous. Net margin has also oscillated downward (13.79% in Q1 to 9.53% in Q3) on a $20.3 million R&D step-up and $52.0 million in sales and marketing, and ROE of just 2.89% reflects a goodwill-heavy balance sheet from the company's leveraged history. Revenue concentration in the U.S. healthcare provider market and dependence on continued cross-sell of payments and AI modules add execution risk to the growth story.
Market and competitive risks are dominated by valuation compression and volatility. At $28.35 the stock sits at essentially 100% of its 52-week range (high of $29.69 set November 4), having roughly doubled off its $17.31 June low — a move that leaves little margin for error at resistance. The -56.31% maximum drawdown and the roughly 70% five-month rally make clear this is a high-volatility, high-beta name that demands smaller position sizing and wider stops. Coverage is thin at six analysts, and the only recent rating action was Barclays downgrading to Equal Weight on September 15, 2026, with no offsetting upgrades — sell-side conviction is comfortable but not rising. Competitive disruption from larger EHR and RCM platforms, plus regulatory pressure on healthcare billing and reimbursement, could pressure pricing and cross-sell momentum.
In a worst-case scenario, a Q4 earnings miss or guidance cut — driven by slower cross-sell, higher interest expense, or margin compression from R&D and S&M investment — would puncture the forward-EPS thesis and force multiple compression on a stock already at its highs. A retest of the $24-$25 September shelf would represent roughly -12% to -15% from $28.35, while a full mean-reversion to the $17.31 June low would imply a loss of approximately -39%. The -56.31% historical max drawdown shows the stock is capable of far worse in a genuine de-rating. Realistically, an adverse scenario of -15% to -25% (to the $21-$24 range) is the most probable downside if the forward earnings estimate slips, with the $17.31 low as the tail-risk floor.
FAQ
The most severe risk is the earnings bridge: trailing GAAP EPS of $0.019 must jump to a forward $2.735, and interest expense of roughly $19-$21 million per quarter consumes a large share of the $41.97 million Q3 pre-tax income, leaving interest coverage at only ~3.2x. Second is margin and execution risk — quarterly net margin fell from 13.79% in Q1 to 9.53% in Q3 2026 on a $20.3 million R&D step-up and $52.0 million in sales and marketing, and ROE is just 2.89% on a goodwill-heavy balance sheet. Third is valuation and volatility risk: the stock sits at 100% of its 52-week range after roughly doubling off its $17.31 June low, with a -56.31% historical max drawdown and thin six-analyst coverage where the only recent action was a Barclays downgrade to Equal Weight. Fourth is competitive and regulatory risk — pressure on healthcare reimbursement and pricing from larger EHR and RCM platforms could slow the cross-sell of payments and AI modules that underpins the growth thesis.
The 12-month outlook splits into three scenarios. The base case (50% probability) targets $30-$34, assuming FY EPS of roughly $2.735 on revenue near $1.878 billion, gross margins in the high-60s, and modest multiple expansion to 11-12.5x forward EPS as confidence in the earnings step-up builds. The bull case (25% probability) targets $36-$40, requiring revenue growth above 20%, gross margin past 70%, interest expense below $19 million per quarter, and multiple expansion to 13-14x the $2.881 high EPS estimate. The bear case (25% probability) targets $21-$25, driven by a Q4 miss, FY2027 guidance below the $1.845 billion low revenue estimate, or EPS drifting toward $2.672. The base case is most likely, and its key assumption is that the forward earnings step-up is delivered — if Q4 confirms gross margin above 70% and guidance at or above $2.80 EPS, the probabilities shift toward the bull case.
The answer depends on which earnings base you use. On trailing GAAP EPS of $0.019 the PE is 51.98x, which looks expensive, but that figure is distorted by interest expense and one-time items and is a poor guide to the underlying economics. On consensus forward EPS of $2.735 the stock trades at roughly 10.4x, and on EV/EBITDA — the cleanest metric for a levered, D&A-heavy software business — it sits at 18.61x, reasonable for a high-teens-growth healthcare IT platform. Against its own history the re-rating is stark: PS has fallen from 25.94x in Q4 2024 to 5.30x today, PE from 81.88x in Q4 2025 to 39.59x in Q3 2026, and PB from 2.05x to 1.20x. The market is therefore pricing in skepticism that the forward earnings step-up will be delivered; if it is, the stock is undervalued relative to its history, and if it is not, the trailing multiple is a warning rather than an artifact.
From a risk/reward standpoint, WAY offers an asymmetric setup: at $28.35 it trades at roughly 10.4x the $2.735 consensus FY EPS and 18.61x EV/EBITDA, near the bottom of its post-IPO valuation band, while revenue is accelerating at 21.21% YoY and free cash flow conversion runs at 90.4%. The six-analyst consensus is uniformly Buy-equivalent with a tight ~8% EPS estimate spread ($2.672-$2.881), signaling conviction rather than uncertainty. The biggest downside risk is that the forward EPS step-up from trailing GAAP EPS of $0.019 fails to materialize, which could send shares back toward the $24-$25 shelf (-12% to -15%) or the $17.31 June low (-39%) in a deeper de-rating. It is a good buy for investors with a 12-24 month horizon who can tolerate a -56.31% historical max drawdown and size positions accordingly, but less suitable for short-term traders given the stock already sits at 100% of its 52-week range after a 32.6% six-month run.
WAY is better suited to a medium-to-long-term holding period of at least 12-24 months than to short-term trading. The thesis is fundamentally about a multi-quarter earnings step-up — forward EPS of $2.735 versus trailing GAAP EPS of $0.019 — which requires interest costs to fall and operating leverage to materialize over several reporting cycles, not a single catalyst. The stock's volatility profile argues against short-term positioning: a -56.31% max drawdown, a roughly 70% move off the June low within five months, and a 1.84% single-session pullback on the most recent day make timing difficult, and the stock already sits at 100% of its 52-week range. There is no dividend support (0% yield, 0% payout), so total return depends entirely on price appreciation and multiple expansion. A concrete minimum holding period of 12 months aligns with the Q4 2026 print and FY2027 guidance cycle, with position sizing kept modest given the volatility.